

## LIST OF FIGURES

FIGURE	TITLE	PAGE NUMBER
1	Protocol 002: HPV 16 Serum RIA GMTs and 95% CIs Through Month 36 (Per protocol population)	29
2	Protocol 004: Plot of Percentage of Subjects with Anti-HPV 16 Serum cRIA Levels $\geq 20$ mMU/mL at 4 weeks postdose 3 and 95% CIs by Vaccination Group (Per Protocol Population)	34
3	Protocol 004: Plot of anti-HPV 16 Serum cRIA GMTs (mMU/mL) and 95% CI in Baseline Seronegative and Seropositive Subjects who Received the 40 mcg dose of vaccine (Subjects who completed the Month 24 Visit Only)	35
4	Month 7 Anti-HPV 16 Serum cRIA Level by Pseudoneutralization Status by Vaccination Group (All HPV 16 Naïve Subjects with Serology Population)	36
5	Protocol 006: Anti-HPV 18 cRIA GMTs with 95% CIs Following Vaccination with HPV 18 L1 VLP Vaccine (Per Protocol Population)	42
6	Protocol 015: Plot of Time to HPV 16/18 Related CIN 2/3 or Worse Diagnosis Through 2.5 Years of Follow-up (MITT-3 Population)	70
7	Protocol 015: Plot of Time to CIN 2/3 or Worse Diagnosis Through 2.5 Years of Follow-up (RMITT-2 Population)	79
8	Protocol 015: Plot of Time to CIN 2/3 or Worse Diagnosis Through 2.5 Years of Follow-up (MITT-3 Population)	80
9	Protocol 015-Consistency Lot Substudy: Longitudinal Plot of Anti-HPV 6 Serum cLIA Responses (PPI Population)	110
10	Protocol 015-Consistency Lot Substudy: Longitudinal Plot of Anti-HPV 11 Serum cLIA Responses (PPI Population)	111
11	Protocol 015-Consistency Lot Substudy: Longitudinal Plot of Anti-HPV 16 Serum cLIA Responses (PPI Population)	112
12	Protocol 015-Consistency Lot Substudy: Longitudinal Plot of Anti-HPV 18 Serum cLIA Responses (PPI Population)	113
13	Protocol 013: Plot of Time to HPV 6/11/16/18 Related CIN Diagnosis (MITT-3 Population)	148
14	Protocol 013: Plot of Time to HPV 6/11/16/18 Related EGL Diagnosis (MITT-3 Population)	154
15	Protocol 013: Plot of Time to EGL Diagnosis (RMITT-2 Population)	161
16	Protocol 013: Plot of Time to EGL Diagnosis (MITT-3 Population)	162

FIGURE	TITLE	PAGE NUMBER
17	Reverse Cumulative Distribution of Anti-HBs Titers at Month 7 – Hepatitis B Vaccination Groups (Hep B PPI)	175
18	Protocol 013: Longitudinal Plot of Anti-HPV 6 Serum cLIA Responses (PPI Population)	180
19	Protocol 013: Longitudinal Plot of Anti-HPV 11 Serum cLIA Responses (PPI Population)	181
20	Protocol 013: Longitudinal Plot of Anti-HPV 16 Serum cLIA Responses (PPI Population)	182
21	Protocol 013: Longitudinal Plot of Anti-HPV 18 Serum cLIA Responses (PPI Population)	183
22	Protocol 007: Longitudinal Plot of Anti-HPV 6 Serum cLIA Responses (PPI Population) (Dose Ranging Phase)	225
23	Protocol 007: Longitudinal Plot of Anti-HPV 11 Serum cLIA Responses (PPI Population) (Dose Ranging Phase)	226
24	Protocol 007: Longitudinal Plot of Anti-HPV 16 Serum cLIA Responses (PPI Population) (Dose Ranging Phase)	227
25	Protocol 007: Longitudinal Plot of Anti-HPV 18 Serum cLIA Responses (PPI Population) (Dose Ranging Phase)	228
26	Protocol 005: Longitudinal Plot of Anti-HPV 16 Serum cLIA Responses (PPI Population)	257
27	Protocol 005: Distribution of Anti-HPV 16 cRIA Levels at Month 7 in the HPV 16 Vaccine Group (PPE Population)	258
28	Protocol 016: Month 7 Titers in 17 Subjects in the PPI Population Who Failed to become Anti-HPV 16 and/or Anti-HPV 18 Seropositive at Month 3 but Became Seropositive to Both types at Month 7 compared to PPI population GMTs	279
29	Protocols 007, 013, 015, and Protocol 005: Plots of Time to Diagnosis of CIN 2/3 or Worse Due to Any HPV Type in the MITT-3 Population	342
30	Protocols 007, 013, 015 Combined: Analysis of Time to HPV 6/11/16/18 Related EGL – MITT-3 Population	352
31	Protocols 005, 007, 013, 015: Plot of Time to Diagnosis of CIN 2 or worse Irrespective of HPV Type – MITT-3 Population	356
32	Protocols 007, 013, 015 Combined: Analysis of Time to Any EGL Irrespective of HPV Type – MITT-3 Population	358
33	Protocols 007, 013, 015, 016, 018: Month 7 HPV 6 cLIA GMTs and 95% CIs at Enrollment: 9-16 year old Female Recipients of Gardasil (PPI)	440

TABLE	TITLE	PAGE NUMBER
34	Protocols 007, 013, 015, 016, 018: Month 7 HPV 11 cLIA GMTs and 95% CIs at Enrollment: 9-16 year old Female Recipients of Gardasil (PPI)	441
35	Protocols 007, 013, 015, 016, 018: Month 7 HPV 16 cLIA GMTs and 95% CIs at Enrollment: 9-16 year old Female Recipients of Gardasil (PPI)	442
36	Protocols 007, 013, 015, 016, 018: Month 7 HPV 18 cLIA GMTs and 95% CIs at Enrollment: 9-16 year old Female Recipients of Gardasil (PPI)	443
37	Persistence of Anti-HPV 6 cLIA Responses in 18-26 year old Female Recipients – Gardasil Recipients Seronegative at Day 1 and PCR Negative Through Month 7 (PPI) versus Placebo Recipients Seropositive and PCR Negative at Day 1 (Cohorts with Serology Data at All Times)	447
38	Persistence of Anti-HPV 11 cLIA Responses in 18-26 year old Female Recipients – Gardasil Recipients Seronegative at Day 1 and PCR Negative Through Month 7 (PPI) versus Placebo Recipients Seropositive and PCR Negative at Day 1 (Cohorts with Serology Data at All Times)	448
39	Persistence of Anti-HPV 16 cLIA Responses in 18-26 year old Female Recipients – Gardasil Recipients Seronegative at Day 1 and PCR Negative Through Month 7 (PPI) versus Placebo Recipients Seropositive and PCR Negative at Day 1 (Cohorts with Serology Data at All Times)	449
40	Persistence of Anti-HPV 18 cLIA Responses in 18-26 year old Female Recipients – Gardasil Recipients Seronegative at Day 1 and PCR Negative Through Month 7 (PPI) versus Placebo Recipients Seropositive and PCR Negative at Day 1 (Cohorts with Serology Data at All Times)	450
41	Reverse Cumulative Distribution Function Plot of the Month 7 anti-HPV 6 cLIA Responses - Immunogenicity Bridging Between Phase III Protocols (PPI Population)	454
42	Reverse Cumulative Distribution Function Plot of the Month 7 anti-HPV 11 cLIA Responses - Immunogenicity Bridging Between Phase III Protocols (PPI Population)	455
43	Reverse Cumulative Distribution Function Plot of the Month 7 anti-HPV 16 cLIA Responses - Immunogenicity Bridging Between Phase III Protocols (PPI Population)	456
44	Reverse Cumulative Distribution Function Plot of the Month 7 anti-HPV 18 cLIA Responses - Immunogenicity Bridging Between Phase III Protocols (PPI Population)	457